Dr. Stephen Hoge, Moderna’s head of R&D, joined the Vanguards of Health Care podcast to share his insights on the company’s groundbreaking work in messenger RNA. In this episode, Dr. Hoge and Bloomberg Intelligence’s Sam Fazeli take listeners into an in-depth conversation on how Covid was just the start of using mRNA as a way of treating disease. They also discuss Moderna’s cancer trials and its approach to rare diseases. 

Dr. Stephen Hoge, Moderna’s head of R&amp;D, joined the Vanguards of Health Care podcast to share his insights on the company’s groundbreaking work in messenger RNA. In this episode, Dr. Hoge and Bloomberg Intelligence’s Sam Fazeli take listeners into an in-depth conversation on how Covid was just the start of using mRNA as a way of treating disease. They also discuss Moderna’s cancer trials and its approach to rare diseases.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare by Bloomberg Intelligence

Moderna’s Hoge on the Next Round of Innovations in mRNA

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/253c2cf4-1ec7-4491-bc09-b1640101da84/transcript

Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,”  Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.

Based on long-term results, &ldquo;the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,&rdquo; &nbsp;Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.

Pulse Biosciences Brings Differentiated Nanosecond Technology to PFA

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f2af8770-3249-48bc-add8-b44a00d2b005/transcript

“I think this is going to be the most eventful ASCO for biotech in a while,” says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast to break down biotech’s rebound, why fundamentals may finally be improving after a prolonged bear market and how China’s speed and cost advantages are reshaping global drug discovery. They also explore AI’s potential to improve clinical success rates, rare-disease regulatory flexibility and why oncology, neuropsych and immunology remain fertile ground for innovation.

&ldquo;I think this is going to be the most eventful ASCO for biotech in a while,&rdquo; says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast to break down biotech&rsquo;s rebound, why fundamentals may finally be improving after a prolonged bear market and how China&rsquo;s speed and cost advantages are reshaping global drug discovery. They also explore AI&rsquo;s potential to improve clinical success rates, rare-disease regulatory flexibility and why oncology, neuropsych and immunology remain fertile ground for innovation.

RTW’s Rod Wong on Biotech’s Revival and the Global Shift

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/45032524-8327-4f41-b472-b442011ec8d4/transcript

“It’s crazy to think that that would be the expectation in cancer care, yet we expect that of families in autism,” says Neil Hattangadi, CEO and co-founder of Cortica. Hattangadi joins Bloomberg Intelligence analyst Jonathan Palmer to explain why autism care remains so fragmented and how Cortica is trying to replace siloed services with a coordinated whole-child model. They discuss why applied behavior analysis (ABA) should be one tool, not the whole answer, how Cortica integrates medical and behavioral care, and why better coordination could ease the burden on families while improving outcomes.

&ldquo;It&rsquo;s crazy to think that that would be the expectation in cancer care, yet we expect that of families in autism,&rdquo; says Neil Hattangadi, CEO and co-founder of Cortica. Hattangadi joins Bloomberg Intelligence analyst Jonathan Palmer to explain why autism care remains so fragmented and how Cortica is trying to replace siloed services with a coordinated whole-child model. They discuss why applied behavior analysis (ABA) should be one tool, not the whole answer, how Cortica integrates medical and behavioral care, and why better coordination could ease the burden on families while improving outcomes.

Cortica’s Plan to Bring Value-Based Care to Autism

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d2a175c4-7e93-4e20-bb23-b43b01309d51/transcript

Moderna’s Hoge on the Next Round of Innovations in mRNA

In 1 playlist(s)

Vanguards of Healthcare by Bloomberg Intelligence

Social links

Follow podcast

Recent clips